Patents by Inventor Karen Baur

Karen Baur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
    Patent number: 9163237
    Abstract: The present invention relates to a replication deficient recombinant virus encoding at least one antigen and/or antigenic epitope, wherein expression of said antigen and/or antigenic epitope is regulated by a transcriptional control element comprising at least two elements driving early expression of said antigen and/or antigenic epitope and the use of said replication deficient recombinant virus as medicament or vaccine.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: October 20, 2015
    Assignee: BAVARIAN NORDIC A/S
    Inventors: Jürgen Hausmann, Karen Baur, Kay Brinkmann
  • REPLICATION DEFICIENT RECOMBINANT VIRUSES EXPRESSING ANTIGENS REGULATED BY TRANSCRIPTIONAL CONTROL ELEMENTS COMPRISING MULTIPLE ELEMENTS
    Publication number: 20140113368
    Abstract: The present invention relates to a replication deficient recombinant virus encoding at least one antigen and/or antigenic epitope, wherein expression of said antigen and/or antigenic epitope is regulated by a transcriptional control element comprising at least two elements driving early expression of said antigen and/or antigenic epitope and the use of said replication deficient recombinant virus as medicament or vaccine.
    Type: Application
    Filed: December 4, 2013
    Publication date: April 24, 2014
    Applicant: Bavarian Nordic A/S
    Inventors: Jürgen HAUSMANN, Karen Baur, Kay Brinkmann
  • Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
    Patent number: 8613936
    Abstract: The present invention relates to a replication deficient recombinant virus encoding at least one antigen and/or antigenic epitope, wherein expression of said antigen and/or antigenic epitope is regulated by a transcriptional control element comprising at least two elements driving early expression of said antigen and/or antigenic epitope and the use of said replication deficient recombinant virus as medicament or vaccine.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: December 24, 2013
    Assignee: Bavarian Nordic A/S
    Inventors: Jürgen Hausmann, Karen Baur, Kay Brinkmann
  • Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
    Patent number: 8394385
    Abstract: The invention is drawn to compositions and methods for the induction of a strong CD8 T cell response to a specific antigen(s). The combination of an early/late hybrid promoter directing strongly enhanced early expression of a neoantigen with at least three immunization rounds resulted in a highly efficient neoantigen-specific CD8 T cell response. This combination reversed the immunodominance hierarchy and converted a moderately immunogenic and subdominant CD8 T cell epitope into the immunodominant epitope.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: March 12, 2013
    Assignee: Bavarian Nordic A/S
    Inventors: Jürgen Hausmann, Karen Baur, Kay Brinkmann
  • REPLICATION DEFICIENT RECOMBINANT VIRUSES EXPRESSING ANTIGENS REGULATED BY TRANSCRIPTIONAL CONTROL ELEMENTS COMPRISING MULTIPLE ELEMENTS
    Publication number: 20120014988
    Abstract: The present invention relates to a replication deficient recombinant virus encoding at least one antigen and/or antigenic epitope, wherein expression of said antigen and/or antigenic epitope is regulated by a transcriptional control element comprising at least two elements driving early expression of said antigen and/or antigenic epitope and the use of said replication deficient recombinant virus as medicament or vaccine.
    Type: Application
    Filed: August 30, 2011
    Publication date: January 19, 2012
    Inventors: Jürgen Hausmann, Karen Baur, Kay Brinkmann
  • OPTIMIZED EARLY-LATE PROMOTER COMBINED WITH REPEATED VACCINATION FAVORS CYTOTOXIC T CELL RESPONSE AGAINST RECOMBINANT ANTIGEN IN MVA VACCINES
    Publication number: 20100233203
    Abstract: The invention is drawn to compositions and methods for the induction of a strong CD8 T cell response to a specific antigen(s). The combination of an early/late hybrid promoter directing strongly enhanced early expression of a neoantigen with at least three immunization rounds resulted in a highly efficient neoantigen-specific CD8 T cell response. This combination reversed the immunodominance hierarchy and converted a moderately immunogenic and subdominant CD8 T cell epitope into the immunodominant epitope.
    Type: Application
    Filed: March 9, 2010
    Publication date: September 16, 2010
    Inventors: JÜRGEN HAUSMANN, KAREN BAUR, KAY BRINKMANN